# OrphanCure Full Pipeline Report: repodb_0ee62470d8ffb2ae

- Drug: Cisplatin
- Disease: Esophageal neoplasm metastatic
- Mode: no_target_expansion
- Status: completed
- Final assessment: Potential

This generated report is for research support only and is not medical advice.

## Structured Output

```json
{
  "sections": {
    "1_executive_summary": {
      "conclusion": "Potential",
      "confidence": "Medium",
      "summary": "Cisplatin is a standard treatment for advanced esophageal cancer, but resistance is a significant clinical challenge. Several studies investigate mechanisms of cisplatin resistance in esophageal cancer, focusing on dysregulated miRNAs, lncRNAs, and specific proteins like FAM111B and HuR. While cisplatin is established in treatment, repurposing efforts would need to address or overcome these resistance mechanisms.",
      "evidence_counts": {
        "total_papers": 59,
        "supporting": 43,
        "contradicting": 6,
        "inconclusive": 10
      },
      "common_targets_count": 0
    },
    "2_normalized_hypothesis": {
      "statement": "Repurpose CISPLATIN for esophageal cancer",
      "drug": {
        "id": "CHEMBL11359",
        "name": "CISPLATIN",
        "aliases": [
          "cis-diamminedichloroplatinum(II)",
          "cis-DDP",
          "DDP",
          "cisplatin",
          "CDDP"
        ],
        "resolution_method": "auto"
      },
      "disease": {
        "id": "MONDO_0007576",
        "name": "esophageal cancer",
        "aliases": [
          "cancer of the esophagus",
          "esophageal carcinoma",
          "esophageal malignancy",
          "cancer, esophagus",
          "esophagus cancer"
        ],
        "resolution_method": "auto"
      }
    },
    "3_mechanistic_rationale": {
      "total_mechanisms": 0,
      "mechanisms": []
    },
    "4_target_overlap_summary": {
      "total_overlapping": 0,
      "top_targets": []
    },
    "5_literature_evidence_summary": {
      "total_retrieved": 59,
      "polarity": {
        "supports": 43,
        "contradicts": 6,
        "inconclusive": 10
      },
      "support_ratio": "43 of 59 retrieved papers support the hypothesis",
      "queries_used": 10,
      "top_papers": [
        {
          "pmid": "38494800",
          "title": "[History and Perspective of Chemotherapy in Advanced Esophageal Cancer].",
          "year": "2024",
          "relevance_score": 11.0,
          "polarity": "CONTRADICTS",
          "match_reasons": [
            "Contradiction signal",
            "Clinical study",
            "Recent"
          ]
        },
        {
          "pmid": "36995552",
          "title": "NGS-based profiling identifies miRNAs and pathways dysregulated in cisplatin-resistant esophageal cancer cells.",
          "year": "2023",
          "relevance_score": 10.5,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        },
        {
          "pmid": "31267531",
          "title": "microRNA-10b confers cisplatin resistance by activating AKT/mTOR/P70S6K signaling via targeting PPAR\u03b3 in esophageal cancer.",
          "year": "2020",
          "relevance_score": 10.5,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Title Match"
          ]
        },
        {
          "pmid": "37672204",
          "title": "Overexpressed FAM111B degrades GSDMA to promote esophageal cancer tumorigenesis and cisplatin resistance.",
          "year": "2024",
          "relevance_score": 10.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        },
        {
          "pmid": "34277424",
          "title": "Downregulation of miR-135b-5p Suppresses Progression of Esophageal Cancer and Contributes to the Effect of Cisplatin.",
          "year": "2021",
          "relevance_score": 10.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Title Match"
          ]
        },
        {
          "pmid": "37401860",
          "title": "LncRNA PVT1 Confers Cisplatin Resistance of Esophageal Cancer Cells through Modulating the miR-181a-5p-Glutaminase (GLS) Axis.",
          "year": "2023",
          "relevance_score": 10.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        },
        {
          "pmid": "39934309",
          "title": "ZCCHC4 regulates esophageal cancer progression and cisplatin resistance through ROS/c-myc axis.",
          "year": "2025",
          "relevance_score": 9.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        },
        {
          "pmid": "40269355",
          "title": "Extracellular transfer of HuR promotes acquired cisplatin resistance in esophageal cancer cells.",
          "year": "2025",
          "relevance_score": 9.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        },
        {
          "pmid": "33644048",
          "title": "Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer.",
          "year": "2021",
          "relevance_score": 9.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Clinical study"
          ]
        },
        {
          "pmid": "40275604",
          "title": "Optimal Primary Prophylaxis for Febrile Neutropenia During Neoadjuvant Cisplatin and 5-Fluorouracil Plus Docetaxel for Esophageal Cancer: A Retrospective Cohort Study.",
          "year": "2025",
          "relevance_score": 9.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        }
      ]
    },
    "6_contradictory_evidence": {
      "count": 0,
      "claims": []
    },
    "7_confidence_assessment": {
      "overall": "Medium",
      "dimensions": {
        "mechanistic_strength": "Medium",
        "literature_strength": "Medium",
        "clinical_evidence": "High"
      },
      "quality_scorecard": {
        "overall_score": 0.767,
        "decision": "finalize",
        "dimensions": {
          "completeness": {
            "score": 1.0,
            "reason": "5/5 sections present"
          },
          "evidence_support": {
            "score": 1.0,
            "reason": "3/3 claims have paper evidence"
          },
          "citation_validity": {
            "score": 0.833,
            "reason": "2 verified, 1 partial out of 3"
          },
          "mechanistic_specificity": {
            "score": 0.0,
            "reason": "0/3 claims reference targets"
          },
          "contradiction_handling": {
            "score": 0.3,
            "reason": "No contradiction analysis"
          },
          "traceability": {
            "score": 1.0,
            "reason": "3/3 claims have provenance"
          },
          "output_structure": {
            "score": 1.0,
            "reason": "Executive summary + confidence assessment"
          },
          "actionability": {
            "score": 1.0,
            "reason": "3 next steps, 3 data gaps identified"
          }
        },
        "weak_dimensions": [
          "mechanistic_specificity",
          "contradiction_handling"
        ],
        "rerun_targets": []
      }
    },
    "8_risk_flags_limitations": {
      "risk_flags": [
        "Cisplatin resistance is a significant challenge in esophageal cancer treatment.",
        "Potential for off-target effects and toxicity associated with cisplatin."
      ],
      "limitations": [
        "The provided literature primarily focuses on mechanisms of cisplatin resistance rather than direct evidence for repurposing beyond its established use.",
        "Lack of randomized controlled trials specifically designed to test cisplatin as a repurposed agent for esophageal cancer.",
        "The majority of studies are preclinical, focusing on cell lines and xenografts."
      ],
      "missing_data": [
        "Direct evidence of cisplatin repurposing for esophageal cancer beyond its current standard of care.",
        "Detailed information on the efficacy of cisplatin in specific subtypes or stages of esophageal cancer.",
        "Data on clinical outcomes from randomized controlled trials specifically evaluating cisplatin as a repurposed agent for esophageal cancer."
      ]
    },
    "9_recommended_next_steps": {
      "clinical_next_steps": [
        "Investigate combination therapies that can overcome cisplatin resistance mechanisms in esophageal cancer.",
        "Explore novel drug delivery systems or formulations to improve cisplatin efficacy and reduce resistance.",
        "Conduct clinical trials to evaluate the efficacy of cisplatin-based regimens in specific patient subgroups identified by molecular profiling."
      ]
    },
    "10_claim_evidence_table": {
      "total_claims": 3,
      "claims": [
        {
          "claim_id": "CLM-51eea3",
          "statement": "Cisplatin is a standard treatment for advanced esophageal cancer.",
          "confidence_numeric": 0.9,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "VERIFIED",
          "targets": [],
          "citation_count": 4,
          "risk_flags": []
        },
        {
          "claim_id": "CLM-575689",
          "statement": "Mechanisms of cisplatin resistance in esophageal cancer involve dysregulation of miRNAs, lncRNAs, and specific proteins.",
          "confidence_numeric": 0.8,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "PARTIALLY_VERIFIED",
          "targets": [],
          "citation_count": 6,
          "risk_flags": []
        },
        {
          "claim_id": "CLM-b71368",
          "statement": "Downregulation of miR-135b-5p suppresses progression of esophageal cancer and contributes to the effect of cisplatin.",
          "confidence_numeric": 0.7,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "VERIFIED",
          "targets": [],
          "citation_count": 2,
          "risk_flags": []
        }
      ]
    },
    "11_provenance_appendix": {
      "total_entries": 3,
      "entries": [
        {
          "claim_id": "CLM-51eea3",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "b02fb0658670",
          "timestamp": "2026-06-03T12:13:44.531678+00:00",
          "paper_evidence": [
            {
              "pmid": "38494800",
              "snippet": "CF(cisplatin plus 5-FU)therapy and taxanes( paclitaxel or docetaxel)were considered standard treatments for first- and second-line treatment of advanced esophageal carcinoma based on the results of ph",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            },
            {
              "pmid": "37672204",
              "snippet": "Chemotherapeutic agents such as cisplatin are commonly used in patients with clinically unresectable or recurrent esophageal cancer (ESCA).",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            },
            {
              "pmid": "37401860",
              "snippet": "Cisplatin (CDDP) is a conventional chemotherapy drug.",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            },
            {
              "pmid": "40269355",
              "snippet": "Cisplatin (DDP) resistance is a key factor hindering esophageal cancer (ESCA) treatment.",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 10
        },
        {
          "claim_id": "CLM-575689",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "b02fb0658670",
          "timestamp": "2026-06-03T12:13:44.531678+00:00",
          "paper_evidence": [
            {
              "pmid": "36995552",
              "snippet": "Resistance to cisplatin, one of the majorly used chemotherapeutic drugs in EC, is a major nuisance. This study sheds light on miRNA dysregulation and its inverse relation with dysregulated mRNAs to gu",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            },
            {
              "pmid": "31267531",
              "snippet": "It is reported that microRNAs (miRNAs) are implicated in chemotherapy resistance of various malignancies. miR-10b was previously proved as an oncogene in multiple malignancies, including esophageal ca",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            },
            {
              "pmid": "37672204",
              "snippet": "However, patients often develop resistance to cisplatin, which in turn leads to a poor prognosis. Studies have shown that FAM111B may be involved in the development of tumors as an oncogene or tumor s",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            },
            {
              "pmid": "37401860",
              "snippet": "However, the acquired cisplatin resistance limits its extensively clinical applications. In this study, the roles and underlying mechanisms of lncRNA PVT1 in cisplatin-resistant ESCA are investigated.",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            },
            {
              "pmid": "39934309",
              "snippet": "ZCCHC4 regulates esophageal cancer progression and cisplatin resistance through ROS/c-myc axis.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": "Quote mismatch (fuzzy check failed)"
            },
            {
              "pmid": "40269355",
              "snippet": "Cisplatin (DDP) resistance is a key factor hindering esophageal cancer (ESCA) treatment. Exosomes have been reported to confer resistance to DDP in various tumor cells.",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 10
        },
        {
          "claim_id": "CLM-b71368",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "b02fb0658670",
          "timestamp": "2026-06-03T12:13:44.531678+00:00",
          "paper_evidence": [
            {
              "pmid": "34277424",
              "snippet": "Our research aimed to reveal the function and mechanism of miR-135b-5p. Our research identified that miR-135b-5p was elevated in EC samples from TCGA database. Correspondingly real-time PCR assay also",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            },
            {
              "pmid": "34277424",
              "snippet": "Moreover, the miR-135b-5p inhibition also inhibited xenograft lump growth. We then predicted the complem...",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 10
        }
      ]
    }
  },
  "metadata": {
    "run_id": "b02fb0658670",
    "created_at": "2026-06-03T12:13:19.272864+00:00",
    "drug": "CISPLATIN",
    "disease": "esophageal cancer",
    "total_claims": 3,
    "quality_score": 0.7666666666666666,
    "reruns": 0
  }
}
```
